Rna Interference

RNAi therapeutics market hots up

RNAi therapeutics market hots up

By Gareth Macdonald

Novartis’ extension of its collaboration with Alnylam Therapeutics and Roche’s acquisition of gene silencing specialist Mirus Bio Corp for $125m (€78.5m) suggest that big pharma is beginning to recognize the commercial potential of RNAi-based therapeutics.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All